ALXO (ALX Oncology Holdings) Margin of Safety % (DCF Earnings Based) : N/A (As of Mar. 28, 2025)

View and export this data going back to 2020. Start your Free Trial

What is ALX Oncology Holdings Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

ALX Oncology Holdings's Predictability Rank is Not Rated. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

Competitive Comparison of ALX Oncology Holdings's Margin of Safety % (DCF Earnings Based)

For the Biotechnology subindustry, ALX Oncology Holdings's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

ALX Oncology Holdings's Margin of Safety % (DCF Earnings Based) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ALX Oncology Holdings's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where ALX Oncology Holdings's Margin of Safety % (DCF Earnings Based) falls into.

Save Embed

;

Save Embed

;

ALX Oncology Holdings Margin of Safety % (DCF Earnings Based) Related Terms

Thank you for viewing the detailed overview of ALX Oncology Holdings's Margin of Safety % (DCF Earnings Based) provided by GuruFocus.com. Please click on the following links to see related term pages.

ALX Oncology Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ALX Oncology Holdings Inc (NAS:ALXO) » Definitions » Margin of Safety % (DCF Earnings Based)

Comparable Companies

Traded in Other Exchanges

N/A

Address

323 Allerton Avenue, South San Francisco, CA, USA, 94080

Website

https://www.alxoncology.com

ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.

Executives

Shelly Pinto	officer: VP, Finance and CAO	866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jaume Pons	director, officer: President and CEO	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Jason Lettmann	director, 10 percent owner	C/O RA PHARMACEUTICALS, INC., 87 CAMBRIDGEPARK DRIVE, CAMBRIDGE MA 02140
Rekha Hemrajani	director	3928 POINT EDEN WAY, HAYWARD CA 94545
Sophia Randolph	officer: Chief Medical Officer	C/O ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
Peter S Garcia	officer: Chief Financial Officer	ALX ONCOLOGY HOLDINGS INC., 866 MALCOLM ROAD, SUITE 100, BURLINGAME CA 94010
J. Scott Garland	director	210 EAST GRAND AVE., SOUTH SAN FRANCISCO CA 94080
Itziar Canamasas	director	C/O ALX ONCOLOGY HOLDINGS INC, 323 ALLERTON AVENUE, SOUTH SAN FRANCISCO CA 94080
Lsv Associates, Llc	10 percent owner	2884 SAND HILL ROAD, SUITE 121, MENLO PARK CA 94025
G. Walmsley Graham	director	ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Vivo Opportunity, Llc	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301
Goodman Corey S	director, 10 percent owner, other: Executive Chairman	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Venbio Global Strategic Fund, L.p.	10 percent owner, other: See Remarks	1700 OWENS STREET, SUITE 595, SAN FRANCISCO CA 94158
Steffen Pietzke	officer: VP Fin & Chief Acct Officer	C/O ENOVIX CORPORATION, 3501 W. WARREN AVENUE, FREMONT CA 94538
Vivo Opportunity Fund, L.p.	10 percent owner	192 LYTTON AVENUE, PALO ALTO CA 94301